Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
Bibliographic Data
| ID | 22069779 |
|---|---|
| Authors | Zhuo-miao Ye, Zhuo‐miao Ye (Central South University), Zi-Qing Tang (Central South University), Zhe Xu (0000-0002-0186-2978, Central South University), Qin Zhou (0000-0002-7192-3887, Central South University), Huan Li (0000-0003-0910-1433, Central South University, corresponding author) |
| Year | 2022 |
| Volume | 10 |
| Pages | 947375-947375 |
| Publication date | 2022-07-22 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2022.947375 |
| PMID | 35937220 |
| OpenAlex | W4286716251 |
| Language | EN |
| References cited | 37 |
Background: The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM. The study is aim to evaluate the cost-effectiveness of Nivolumab plus ipilimumab vs. platinum plus chemotherapy for the first-line treatment of unresectable MPM. Methods: A Markov model was developed to compare the cost and quality-adjusted life-year (QALY) of nivolumab plus ipilimumab and chemotherapy over a 10-year time horizon. Clinical efficacy and safety data were extracted from the CheckMate 743 trials. Health state utilities were obtained from published literature. Costs were collected from an US payer perspective. One-way and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on the cost-effectiveness's results. Results: In the base case analysis, the incremental healthcare costs and QALYs for Nivolumab plus Ipilimumab vs. chemotherapy are $196,604.22 and 0.53, respectively, resulting an incremental cost-effectiveness ratio (ICER) of $372,414.28/QALYs for the model cohort of patients with locally advanced or metastatic MPM. However, Probabilistic sensitivity analysis showed that there was no probability that Nivolumab plus ipilimumab was cost-effective within the fluctuation range of other model parameters in first-line in unresectable MPM. The results of one-way sensitivity analysis showed that the cost of Nivolumab was the most sensitive parameter. Conclusions: The ICER of Nivolumab plus ipilimumab is above the theoretical willingness-to-pay threshold in the U.S, which suggests that first-line nivolumab plus ipilimumab for unresectable MPM may be not a cost-effective choice
Cancer · Chemotherapy · Cost effectiveness · First line treatment · Immunotherapy · Ipilimumab · Mesothelioma · Nivolumab · Pathology · Cancer Immunotherapy and Biomarkers · Medicine · Myasthenia Gravis and Thymoma · Occupational and environmental lung diseases · Internal Medicine · Oncology
| Citation velocity | historical |
|---|---|
| Highly cited | No |